RAF1 and cancer: Finally, DRx-170 was evaluated against three additional non-PDAC KRASMT cancer cell lines (HCT116, NCI-H460, A549) and a RAS-RAF wild-type cancer cell line (U2-OS) (Figs. S7, S8).